Clinical Trials Logo

Syndrome clinical trials

View clinical trials related to Syndrome.

Filter by:

NCT ID: NCT03611283 Completed - Sjogren's Syndrome Clinical Trials

Topical Management of Xerostomia With Dry Mouth Products

Start date: October 3, 2016
Phase: N/A
Study type: Interventional

Objectives: To assess the effects of topical dry mouth products (toothpaste and mouthwash) containing olive oil, parsley oil, provitamin B5, allantoin, betaine and xylitol in Primary Sjögren's syndrome patients with xerostomia. Subjects and Methods: A double-blinded, placebo-controlled, randomized design where participants were randomly assigned at baseline test or placebo products. Participants used the products 3 times/day/28 days. The investigators used Visual Analog Scale for xerostomia and Oral Health Impact Profile-14, baseline and after treatment, to assess the possible improvement.

NCT ID: NCT03611140 Completed - Metabolic Syndrome Clinical Trials

Effect of Functional Foods on Gut Microbiota in Metabolic Syndrome

MetS
Start date: January 10, 2014
Phase: N/A
Study type: Interventional

Aim: To study the effect of a combination of functional foods on gut microbiota in subjects with metabolic syndrome. Subjects that met the metabolic syndrome criteria were enrolled in a double-blind, parallel-arm, placebo-control study. The subjects were randomized to receive a dietary portfolio (DP) or placebo (P) treatment for 2 mo. The primary endpoint was to study the effect of a DP on gut microbiota. Secondary endpoints were biochemical and anthropometric parameters, LPS, insulin, leptin, area under the curve for glucose and insulin.

NCT ID: NCT03610139 Recruiting - Multiple Sclerosis Clinical Trials

Longitudinal Effect of Vitamin D3 Replacement on Cognitive Performance and MRI Markers in Multiple Sclerosis Patients

Start date: May 21, 2018
Phase: N/A
Study type: Interventional

This is a longitudinal single blind randomized trial to test the effects of high compared to low dose vitamin D3 supplementation on cognitive performance at 6 and 12 months, and MRI measures of 12 months duration. A cognitive assessment battery will be administered at baseline, 6 and 12 months. Related clinical data and information on depression and anxiety, lifestyle, and food sources of vitamin D and sun exposure among other variables will also be collected.

NCT ID: NCT03609385 Completed - Clinical trials for Acute Coronary Syndrome

PRediction of Acute Coronary Syndrome in Acute Ischemic StrokE

PRAISE
Start date: August 1, 2018
Phase:
Study type: Observational

The primary goal of the PRAISE study is to develop a diagnostic algorithm that allows the prediction of acute coronary syndrome in stroke patients with elevated levels of cardiac troponin.

NCT ID: NCT03608800 Completed - Metabolic Syndrome Clinical Trials

Potential Effects of Intermittent Fasting to Metabolic Syndrome

Start date: June 30, 2018
Phase: N/A
Study type: Interventional

The survey is designed to investigate whether 8 weeks of discrete two-day intermittent fasting per week will impact gut microbiota and cardiovascular risks of metabolic syndrome subjects.

NCT ID: NCT03608761 Completed - Dry Eye Syndromes Clinical Trials

Comparison Between Rebamipide 2% Versus Autologous Serum

Start date: February 6, 2017
Phase: Phase 4
Study type: Interventional

Two-period, controlled, randomized and open clinical trial. The sample was composed of adult women with moderate to severe hypo secretory dry eye associated with Sjögren's syndrome, who attended the ocular surface office, derived from the general ophthalmology clinic, from the Rheumatology or Immunology department. The three interventions were randomized: autologous serum (GSA), Rebamipida 2% (GR) and a combined treatment (GSAR). The following were used as outcome measures: OSDI self-administered questionnaire (Ocular Surface Disease Index), tear-rupture time (BUT), fluorescein staining, Bengal Rose staining and Schirmer's test without anesthesia to assess the answer to each treatment

NCT ID: NCT03608696 Completed - Clinical trials for Neonatal Abstinence Syndrome

Buprenorphine Pharmacometric Open Label Research Study of Drug Exposure

B-PHORE
Start date: August 29, 2018
Phase: Phase 1/Phase 2
Study type: Interventional

Neonatal withdrawal syndrome is a series of signs and symptoms in infants exposed to opioids in utero. Buprenorphine has demonstrated a 40% reduction in length of pharmacologic treatment compared to oral morphine. These results were with an empirically derived dose. This study will use pharmacokinetic modeling-informed dosing to clarify the dose/response relationship and use a rational approach to define an optimal dose regimen. The clinical trial will be open label, single arm design with a goal of initial testing of a new dosing regimen.

NCT ID: NCT03608592 Recruiting - Clinical trials for Acute Respiratory Distress Syndrome

Human Umbilical Cord Mesenchymal Stem Cells (MSCs) Therapy in ARDS

ARDS
Start date: June 1, 2018
Phase: N/A
Study type: Interventional

Acute respiratory distress syndrome (ARDS) is a devastating inflammatory and destructive disease in critical ill patients. Preclinical studies have shown a promising perspective of mesenchymal stem cells (MSCs) therapies in ARDS. But the safety and efficacy of umbilical cord MSCs (UCMSCs) have not yet been convinced in clinical trails. This study will explore the safety and life-rescue potential of UCMSCs in refracotry ARDS.

NCT ID: NCT03607201 Completed - Heart Failure Clinical Trials

Acute Coronary Syndrome in Diabetic Patients

Start date: August 1, 2017
Phase:
Study type: Observational

This study aims to compare the clinical profile and outcomes of acute coronary syndrome patients with diabetes and without diabetes.

NCT ID: NCT03606408 Completed - Cushing's Syndrome Clinical Trials

Roll-over Study in Patients With Endogenous Cushing's Syndrome for LCI699

Start date: October 5, 2018
Phase: Phase 2
Study type: Interventional

The purpose of this study is the evaluation of long-term safety of osilodrostat in patients who have already received osilodrostat treatment in a previous Global Novartis-sponsored trial and who, based on investigators' judgement, will continue benefiting with its administration.